Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder.
about
The alpha-2A adrenoceptor agonist guanfacine improves sustained attention and reduces overactivity and impulsiveness in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD)European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHDEvidence-based information on the clinical use of neurofeedback for ADHDHypericum perforatum (St John's wort) for attention-deficit/hyperactivity disorder in children and adolescents: a randomized controlled trialAnimal models of attention-deficit hyperactivity disorder.Natural Product-Derived Treatments for Attention-Deficit/Hyperactivity Disorder: Safety, Efficacy, and Therapeutic Potential of Combination TherapyU-shaped relation between plasma oxytocin levels and behavior in the trust gameIndividual and combined effects of physical exercise and methylphenidate on orienting behavior and social interaction in spontaneously hypertensive rats.Physical exercise and catecholamine reuptake inhibitors affect orienting behavior and social interaction in a rat model of attention-deficit/hyperactivity disorderl-Amphetamine improves poor sustained attention while d-amphetamine reduces overactivity and impulsiveness as well as improves sustained attention in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD)Quantitative trait locus analysis identifies rat genomic regions related to amphetamine-induced locomotion and Galpha(i3) levels in nucleus accumbens.Impulsiveness, overactivity, and poorer sustained attention improve by chronic treatment with low doses of l-amphetamine in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD).Attention Deficit Hyperactivity Disorder Symptoms and Low Educational Achievement: Evidence Supporting A Causal HypothesisNew methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder.Clinically Significant Symptom Reduction in Children with Attention-Deficit/Hyperactivity Disorder Treated with Micronutrients: An Open-Label Reversal Design StudyTraditional Oriental Herbal Medicine for Children and Adolescents with ADHD: A Systematic Review.A comparison of comorbidity and psychological outcomes in children and adolescents with attention-deficit/hyperactivity disorder.Efficacy and safety of modafinil film-coated tablets in children and adolescents with or without prior stimulant treatment for attention-deficit/hyperactivity disorder: pooled analysis of 3 randomized, double-blind, placebo-controlled studies.Modulation of high impulsivity and attentional performance in rats by selective direct and indirect dopaminergic and noradrenergic receptor agonistsPhysical exercise affects attentional orienting behavior through noradrenergic mechanisms.A pilot study for augmenting atomoxetine with methylphenidate: safety of concomitant therapy in children with attention-deficit/hyperactivity disorderAttention-deficit/hyperactivity disorder: advancing on pharmacogenomics.Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.Innovations and recent trends in the treatment of ADHD.Attention-deficit/hyperactivity disorder: neurophysiology, information processing, arousal and drug development.Co-occurrence of bipolar and attention-deficit hyperactivity disorders in children.Treatment strategies for co-occurring ADHD and substance use disordersThe use of antipsychotics in children and adolescents with bipolar disorders.Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: A randomized, double-blind, placebo-controlled studyMethylphenidate enhances the abuse-related behavioral effects of nicotine in rats: intravenous self-administration, drug discrimination, and locomotor cross-sensitization.Atomoxetine improves patient and family coping in attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in Swedish children and adolescents.Acute dose-related differential effects of methylphenidate on murine cystometric parameters.Sex-dependent changes in ADHD-like behaviors in juvenile rats following cortical dopamine depletion.Comparison of Two brands of Methylphenidate (Stimdate(®) vs. Ritalin(®)) in Children and Adolescents with Attention Deficit Hyperactivity Disorder: A Double-Blind, Randomized Clinical Trial.Long-term treatment of ADHD with stimulants: a large observational study of real-life patients.The clinical impact of switching attention deficit hyperactivity disorder patients from OROS(®)-MPH to Novo-MPH ER-C(®): A paediatric practice review.Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder During Adolescence in the Primary Care Setting: A Concise ReviewADHD in old age: a review of the literature and proposal for assessment and treatment.Cross-species studies of cognition relevant to drug discovery: a translational approach.Atomoxetine increases salivary cortisol in healthy volunteers.
P2860
Q21203889-0AA03BF3-CC60-4663-8067-01132F451194Q21260332-AA9F20AE-07C2-47D5-8EC4-5CCF4C3BBBC3Q24600947-3EF8443E-3AF6-4A67-966A-5D54C120DDAFQ24653919-C9940BBE-07D2-4D05-A0D1-A6E3EBB59846Q24814868-49346190-4E89-48B4-8B42-7901E3C05DE0Q26766330-58EC5BF3-D6AB-49C6-8CBF-94C6DADCCB3BQ28485462-70738A7C-AD8B-4038-9C00-065E52B1FF26Q30397085-6E8E12AB-A6AB-47E6-8A20-86C9EA7CF589Q30446474-15CA3466-634B-44EC-94B3-C63E16B0AF09Q30481412-F85A4D33-AEE4-4A80-90C4-8122D1D915D6Q30483465-08C87F36-80F4-4A14-B518-37CBAFFB286BQ30500047-FFE2F7D5-7740-4081-9B56-8A637BAE5D45Q33600028-B0DB96AB-97B4-4646-BAF1-BDE1CE6BFDE5Q34468658-0EE1F5A9-4AFD-4431-A481-C58D8E8E434BQ34505716-3F3701B7-680C-4204-B20E-AB3466A78A3CQ34560732-8B71B64B-33CB-4CA1-A042-66A1BC1B1577Q35144229-A1CDE086-526C-4E3D-A6CD-0C2BB17BB42AQ35574482-B9B7F868-EE9B-424A-A58F-7635C7C3BBA6Q35644004-AC0592EB-C900-4796-8374-588281CED605Q35672550-A267F0E4-287C-4801-B18C-F42094A3ACD4Q36176008-D3342A1F-9926-4D99-AA14-466B99E3595BQ36192663-271ABB80-B8E8-45AA-A4F5-C8B23FE55F3BQ36492886-76E5142E-29A6-4789-8F85-0D3A65829847Q36607357-15274046-577B-42AC-B195-C4AC0F9292F3Q36673034-48AF5D17-85C5-43C6-8DC1-BC82ECD59906Q36677656-D50E5C98-69D3-46BF-B8F9-4417415AB098Q36799361-5B70E1D0-2005-45D8-A9F0-D4655E873525Q36979293-C9939F41-D78F-4490-BEF5-8FF8D8B509D5Q37141442-6D3740AA-4D84-4369-8B74-381D51B7CC5DQ37147049-B137C29F-EFF9-4DC8-A7F4-27E814573808Q37404950-D8C64422-E193-4D8D-9DB7-F207F3F74BDBQ37492639-E1832340-A745-4ADE-A2DF-45358EA4581FQ37587449-AD7FD74F-456A-42F8-8575-55A96DC2F3F5Q37612811-22490C43-66D9-46D2-A313-1404081F7898Q37772707-7BD5FCEF-8D75-4813-9ED4-6FDB6D80FDC6Q38178250-E4FAE84C-9AF3-4AA8-8C8B-8EAA1914868CQ38840904-8BDAC60B-1769-4BA0-BDF3-BDFC28A99BBDQ38873722-040DEF0D-5A4F-4787-85D9-2E7D7B6646BEQ39256002-A24FA8A8-B131-4050-A2D3-E9CB21283CC8Q40221613-6FF1DAAE-5124-4C92-9CC8-BC54813730CE
P2860
Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder.
@ast
Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder.
@en
type
label
Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder.
@ast
Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder.
@en
prefLabel
Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder.
@ast
Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder.
@en
P1476
Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder.
@en
P2093
Thomas Spencer
Timothy Wilens
P356
10.1017/S1461145703003973
P577
2004-01-21T00:00:00Z